Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

panitumumab

View Patient Information

A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR). Monoclonal antibody E7.6.3 binds to the EGFR, blocking the binding of epidermal growth factor and transforming growth factor alpha to EGFR-expressing cancer cells and ultimately inhibiting EGFR-dependent cell activation and proliferation.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	ABX-EGF monoclonal antibody ABX-EGF, clone E7.6.3 human IgG2K monoclonal antibody monoclonal antibody ABX-EGF monoclonal antibody E7.6.3
US brand name:	Vectibix
Abbreviation:	ABX-EGF MoAb ABX-EGF MoAb E7.6.3
Code name:	E7.6.3

panitumumab

Search NCI's Drug Dictionary